Browning P J, Roberts D D, Zabrenetzky V, Bryant J, Kaplan M, Washington R H, Panet A, Gallo R C, Vogel T
Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
J Exp Med. 1994 Nov 1;180(5):1949-54. doi: 10.1084/jem.180.5.1949.
Recombinant apolipoprotein E-3 (ApoE-3), expressed in Escherichia coli, was purified and used in an in vitro and an in vivo model system for acquired immunodeficiency syndrome-associated Kaposi's sarcoma (AIDS-KS). This protein blocked cell proliferation and chemotaxis of AIDS-KS cells in response to activated lymphocyte conditioned medium (AL-CM) and oncostatin M (OSM). ApoE-3 also inhibited the formation of neoangiogenic lesions induced in BALB/c nu/nu mice by AIDS-KS cells. These findings represent a novel and potentially less toxic therapeutic approach for the treatment of AIDS-KS.
在大肠杆菌中表达的重组载脂蛋白E-3(ApoE-3)被纯化,并用于获得性免疫缺陷综合征相关卡波西肉瘤(AIDS-KS)的体外和体内模型系统。该蛋白可阻断AIDS-KS细胞对活化淋巴细胞条件培养基(AL-CM)和抑瘤素M(OSM)的细胞增殖和趋化作用。ApoE-3还可抑制AIDS-KS细胞在BALB/c裸鼠中诱导形成的新生血管性病变。这些发现代表了一种治疗AIDS-KS的新的且潜在毒性较小的治疗方法。